A recently completed genome-wide association study (GWAS) implicated single-nucleotide polymorphisms in the MIR137 gene as being highly associated with schizophrenia.
1 MIR137 encodes for the microRNA miR-137, which has been implicated in the regulation of adult neurogenesis 2 and neuron maturation. 3 Strikingly, four predicted targets of miR-137 also achieved genome-wide significance. These findings suggest that the dysregulation or dysfunction of miR-137 may be a novel pathological pathway underlying the etiology of schizophrenia.
In this work, we use a luciferase-based reporter assay to demonstrate the site-specific regulation of CSMD1, C10orf26, CACNA1C and TCF4 by miR-137. Schizophrenia is a spectrum disorder that has a lifetime prevalence of B1%. Disease onset usually occurs during adolescence, and suicide is the leading cause of premature death. Although monozygotic twin studies have clearly shown a genetic basis for this disease, the underlying genetics of schizophrenia have been difficult to delineate. A linkage study of a Scottish family with a high incidence of psychiatric disorders identified a rare, but highly penetrant, mutation in disrupted in schizophrenia-1 (DISC1); 4 however, single-gene mutations have not been found in the vast majority of schizophrenia patients. It is believed that the onset of schizophrenia is due to the accumulation of several gene mutations, each of which has modest phenotypic effects, which are compounded with environmental factors. This complexity has made the identification of contributing genes difficult. Improvements in genotyping technology have allowed for GWAS in large patient populations. However, the results of schizophrenia GWASs have yet to be validated biologically.
In a recent study by the Schizophrenia Psychiatric GWAS consortium, MIR137, along with four of its putative targets (CSMD1, C10orf26, CACNA1C and TCF4) were reported to have genomewide significant associations with schizophrenia. 1 In addition, genes associated with schizophrenia were enriched for predicted miR-137 targets. These findings imply that miR-137 dysregulation or dysfunction may be a pathway that contributes to schizophrenia disease progression. Until this report, schizophrenia GWAS findings have not been linked to the neurobiology of the disease. To investigate the biological relevance of schizophrenia GWAS findings, we used reporter constructs to directly confirm miR-137-mediated knockdown of predicted miR-137 target sequences in the 3 0 -untranslated regions of four putative schizophrenia risk genes.
The CSMD1, C10orf26, CACNA1C and TCF4 predicted miR-137 target gene 3 0 -untranslated regions have either 7mer or 8mer canonical sites and, in some cases, are elaborated with a 3 0 -supplementary site (Figure 1a) , as defined previously. 5 These five sites (TCF4 has two predicted miR-137 sites) and their flanking sequences were cloned into the 3 0 -untranslated region of Renilla luciferase in the psiCHECK-2 vector (Figure 1b ) and co-transfected with either miR-CNTL or miR-137 overexpression constructs at a 1:2 ratio into HEK-293T cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). HEK-293T cells have a low endogenous level of miR-137 expression (data not shown). The psiCHECK-2 vector also includes Firefly luciferase driven by a separate promoter that allows for normalization of signal to transfection efficiencies. When the ratio of Renilla to Firefly luciferase activity was compared between cells transfected with miR-CNTL and those with miR-137, all predicted targeted showed decreased Renilla luciferase activities by 25--50% compared with controls ( Figure 1c) . When the miR-137 7mer site 5 0 -GCAAUAA-3 0 was deleted from each target construct and co-transfected with miR-137, the Renilla/Firefly luciferase ratio did not differ significantly from controls (P40.05 two-way analysis of variance). These results show that miR-137 interacts with the 3 0 -untranslated region sequences from the four predicted targets in a site-specific manner.
MiR-137 has been shown to have a role in epigenetic regulation of adult neural stem cell proliferation 2 and neuronal maturation. This is analogous to the phenotypes following knockdown of the schizophrenia-related gene DISC1. 6 In addition, two predicted miR-137 targets have been previously associated with psychiatric illness. CACNA1C encodes for the a subunit of the voltagedependent L-type calcium channel Ca V 1.2, and has been shown to be associated with bipolar disease. 7 TCF4 encodes a transcription factor involved in the development of a subset of neural progenitors 8 and TCF4-overexpressing transgenic mice show schizophrenia-associated behavior. 9 These studies, and the recent Letters to the Editor findings from the schizophrenia GWAS, further implicate dysregulated miR-137 as a potential contributor to schizophrenia pathology. In this work, we confirm the targeting of miR-137 to four genes significantly associated with schizophrenia, providing the first biological validation of a schizophrenia GWAS.
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Dopaminergic stabilizers are presently being investigated for use in neurological and psychiatric disorders. 4, 5 These agents, which include (-)-OSU6162 and ACR16, have been shown to enhance locomotor activity in animals under conditions of low dopaminergic tone and to decrease activity when dopamine signaling is high, thus owing these drugs their name. 4 The compounds reduce locomotor activity in amphetamine-treated animals, which is indicative of antipsychotic activity and have also been shown to reduce social withdrawal in the ( þ )-MK-801 rat model of negative symptoms in schizophrenia. 6 Dopaminergic stabilizers have also shown clinical promise; the compound ACR16 (also known as pridopidine, or Huntexil) is currently in phase III clinical trials to treat Huntington's disease, 5 and another dopaminergic stabilizer has completed a phase I trial to evaluate its efficacy in reducing L-DOPA-induced dyskinesia (Identifier: NCT01023282). In addition, (À)-OSU6162 and ACR16 have shown antipsychotic activity in patients. 4 In line with the well-established involvement of dopamine signaling in movement and psychiatric disorders, investigations of 0 UTR sequence from predicted miR-137 targets were inserted. Each construct was co-transfected with miR-CNTL (black bars) or miR-137 (gray bars) and the ratio of Renilla/Firefly luciferase activity was normalized to miR-CNTL treatment. When miR-137 7-mer target site was deleted in reporter constructs (white bars), measured ratios were restored to that of the miR-CNTL treatment. Results are reported as the average of four replicates from two independent experiments þ s.e.m., *Po0.01 by two-way analysis of variance.
